COMMUNIQUÉS West-GlobeNewswire

Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
25/02/2026
WARREN, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
ITM to Announce Phase 3 COMPETE Trial Post-Hoc Subgroup Analysis in Pancreatic Neuroendocrine Tumors and Host Satellite Symposium at ENETS 2026
25/02/2026
Garching / Munich, February 25, 2026 – ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, today announced that it will provide further exploratory and post-hoc subgroup analysis [...]
Dyne Therapeutics to Participate in Upcoming Investor Conferences
25/02/2026
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular [...]
Helsinn Healthcare & InVirtuoLabs sign a Strategic Collaboration in AI-Driven Drug Discovery
25/02/2026
Partnership combines Helsinn proprietary compound library with InVirtuoLabs generative AI platform to accelerate discovery of novel therapeutics Lugano, Switzerland – February 25, 2026 – Helsinn Healthcare SA (Helsinn [...]
RYBREVANT®▼ (amivantamab) par voie sous-cutanée, approuvé par la Commission Européenne pour une administration toutes les trois ou quatre semaines chez les patients atteints d’un cancer du poumon non à petites cellules avancé avec mutations de l’EGFR
25/02/2026
L’amivantamab sous-cutané (SC) réduit l’administration de plusieurs heures à quelques minutes, avec une efficacité et une sécurité comparables à celles de l’amivantamab intraveineux (IV) 1 ,2,3,4,5 L’amivantamab SC est [...]
Synklino announces publication in American Journal of Transplantation highlighting proof-of-concept for SYN002 in eliminating CMV in human kidneys
25/02/2026
Preclinical data demonstrate >90% reduction in human cytomegalovirus (HCMV) reactivation from latency, establishing proof-of-concept for SYN002 in human kidneys Data published in the American Journal of [...]
ICPO Foundation and the World Federation of Nuclear Medicine and Biology (WFNMB) cooperate to advance Theranostics worldwide
25/02/2026
The strategic partnership will also support the WHO resolution WHA78.13 with the aim to improve access to medical imaging and nuclear medicine February 25, 2026 – Wiesbaden, Germany. The International Centers for [...]
Novonesis' Annual Report 2025
25/02/2026
Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall. Ester Baiget, President & CEO: ”In 2025, we [...]
Ethris Part of Consortium to Receive up to EUR 148 Million European Commission Contract to Advance Novel Pandemic Influenza Vaccine
25/02/2026
Initial tender contract of EUR 13 million supports gated advancement into two subsequent competitive phases MUNICH, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ethris GmbH , a clinical-stage biotechnology company pioneering next- [...]
Incentive programs for the Executive Leadership Team, the Senior Leadership Team and directors, and other employees
25/02/2026
Please read the full announcement in PDF Attachment 2026_02_LTI
35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)
25/02/2026
Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary diseases HS235 offers potential to treat pulmonary hypertension (PH) patients [...]
Novonesis delivered strong organic sales growth of 7% in 2025
25/02/2026
COPENHAGEN, Denmark – February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall. Ester [...]
Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
25/02/2026
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 25, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of [...]
Ivim Health GLP-1 Weight Loss Program: Individualized Dosing, Pricing, and What Consumers Should Know in 2026
25/02/2026
An informational overview of Ivím Health's compounded semaglutide and tirzepatide telehealth program, including GLP-1 ID cost breakdown, weekly provider check-in structure, clinical claims analysis, and safety [...]
Pulmo Balance: Ingredients, Pricing, and What Consumers Should Know in 2026
25/02/2026
An informational overview examining category context, publicly available product disclosures, and what consumers often consider when researching respiratory support supplement options New York, NY, Feb. 24, 2026 (GLOBE [...]
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
25/02/2026
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)
25/02/2026
SHANGHAI, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Rapport Therapeutics to Participate in Upcoming Investor Conferences
24/02/2026
BOSTON and SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small [...]
Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results
24/02/2026
SUNNYVALE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]

Pages